CN102462776A - 一种治疗心脑血管疾病的中药组合物及其制备方法和用途 - Google Patents
一种治疗心脑血管疾病的中药组合物及其制备方法和用途 Download PDFInfo
- Publication number
- CN102462776A CN102462776A CN2010105437100A CN201010543710A CN102462776A CN 102462776 A CN102462776 A CN 102462776A CN 2010105437100 A CN2010105437100 A CN 2010105437100A CN 201010543710 A CN201010543710 A CN 201010543710A CN 102462776 A CN102462776 A CN 102462776A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- medicine composition
- polygoni cuspidati
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 62
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 20
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 20
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 93
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 65
- 241000628997 Flos Species 0.000 claims description 43
- 229940079593 drug Drugs 0.000 claims description 33
- 239000000843 powder Substances 0.000 claims description 29
- 238000005303 weighing Methods 0.000 claims description 26
- 239000000284 extract Substances 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000012141 concentrate Substances 0.000 claims description 13
- 239000009636 Huang Qi Substances 0.000 claims description 12
- 241000245240 Lonicera Species 0.000 claims description 12
- 241001530126 Scrophularia Species 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 238000010992 reflux Methods 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- 238000001291 vacuum drying Methods 0.000 claims description 8
- 241000545442 Radix Species 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 28
- 210000004369 blood Anatomy 0.000 abstract description 26
- 239000008280 blood Substances 0.000 abstract description 26
- 238000011282 treatment Methods 0.000 abstract description 16
- 150000002632 lipids Chemical class 0.000 abstract description 12
- 239000002552 dosage form Substances 0.000 abstract description 9
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 5
- 208000037260 Atherosclerotic Plaque Diseases 0.000 abstract description 4
- 210000001367 artery Anatomy 0.000 abstract description 3
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 206010014080 Ecchymosis Diseases 0.000 abstract 1
- 244000153955 Reynoutria sachalinensis Species 0.000 abstract 1
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 abstract 1
- 229910000368 zinc sulfate Inorganic materials 0.000 abstract 1
- 235000009529 zinc sulphate Nutrition 0.000 abstract 1
- 239000011686 zinc sulphate Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 239000002775 capsule Substances 0.000 description 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 10
- 108010023302 HDL Cholesterol Proteins 0.000 description 9
- 201000005577 familial hyperlipidemia Diseases 0.000 description 9
- 108010028554 LDL Cholesterol Proteins 0.000 description 8
- 239000003172 expectorant agent Substances 0.000 description 8
- 230000003419 expectorant effect Effects 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 6
- 229960002855 simvastatin Drugs 0.000 description 6
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000006189 buccal tablet Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 229940046011 buccal tablet Drugs 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 230000000923 atherogenic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- -1 filters Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010105437100A CN102462776A (zh) | 2010-11-15 | 2010-11-15 | 一种治疗心脑血管疾病的中药组合物及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010105437100A CN102462776A (zh) | 2010-11-15 | 2010-11-15 | 一种治疗心脑血管疾病的中药组合物及其制备方法和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102462776A true CN102462776A (zh) | 2012-05-23 |
Family
ID=46067084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010105437100A Pending CN102462776A (zh) | 2010-11-15 | 2010-11-15 | 一种治疗心脑血管疾病的中药组合物及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102462776A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105012413A (zh) * | 2015-08-28 | 2015-11-04 | 南京中医药大学 | 一种具有降血脂作用的中药组合物及其制备方法与应用 |
CN107468917A (zh) * | 2017-08-11 | 2017-12-15 | 湖南中医药大学 | 一种化痰解毒治疗冠心病的中药组合物及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101125190A (zh) * | 2007-07-26 | 2008-02-20 | 关艳龙 | 粉状药物活性炭混合物及其制备方法 |
-
2010
- 2010-11-15 CN CN2010105437100A patent/CN102462776A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101125190A (zh) * | 2007-07-26 | 2008-02-20 | 关艳龙 | 粉状药物活性炭混合物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
何剑平: "高脂血症辨证治疗进展", 《辽宁中医学院学报》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105012413A (zh) * | 2015-08-28 | 2015-11-04 | 南京中医药大学 | 一种具有降血脂作用的中药组合物及其制备方法与应用 |
CN105012413B (zh) * | 2015-08-28 | 2018-10-19 | 南京中医药大学 | 一种具有降血脂作用的中药组合物及其制备方法与应用 |
CN107468917A (zh) * | 2017-08-11 | 2017-12-15 | 湖南中医药大学 | 一种化痰解毒治疗冠心病的中药组合物及其应用 |
CN107468917B (zh) * | 2017-08-11 | 2020-12-04 | 湖南中医药大学 | 一种化痰解毒治疗冠心病的中药组合物及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101239112B (zh) | 调节血脂的中药组合物及其制备方法 | |
CN103041118B (zh) | 一种具有降血糖降血脂作用的组合物 | |
CN102366605A (zh) | 一种治疗高血压高血脂的中药制剂及制备方法 | |
CN106177053A (zh) | 一种包含青钱柳叶和陈皮的降血糖保健组合物 | |
CN101011562B (zh) | 参芪温胆汤新剂型及其生产方法 | |
CN1558768A (zh) | 一种中药组合物及其制备方法 | |
CN101461932B (zh) | 一种治疗小儿脾虚湿热腹泻的药物组合物及其制备方法 | |
CN102462776A (zh) | 一种治疗心脑血管疾病的中药组合物及其制备方法和用途 | |
CN105582124A (zh) | 一种治疗便秘的中药及其制备方法 | |
CN101912434B (zh) | 一种用于治疗高血压、失眠症的药物及其制备方法 | |
CN110090253B (zh) | 一种天然植物降脂组合物及其制备方法 | |
CN101480472B (zh) | 调血脂的药物及生产方法 | |
CN106581236A (zh) | 一种促进胃动力的药物组合物及其制备方法和应用 | |
CN102846720B (zh) | 一种降血脂、提高缺氧耐受力的组合物 | |
CN105727089A (zh) | 含艾叶的药物组合物用于制备治疗肠易激综合症药物中的用途 | |
CN105535587A (zh) | 一种治疗心肾不交型心悸失眠的中药制剂及其制备方法 | |
CN105250954A (zh) | 一种治疗肠易激综合征的中药及其制备方法 | |
CN109125623A (zh) | 一种用于治疗肝病的药物组合物 | |
CN112089783B (zh) | 中药组合物在制备预防或/和治疗肥胖的药物中的应用 | |
CN101695534B (zh) | 治疗乳腺疾病的中成药 | |
CN101164595A (zh) | 一种治疗厌食症的中药 | |
CN100435842C (zh) | 治疗高血压病的中药制剂及制备方法 | |
CN108619108B (zh) | 参七心疏胶囊的应用及其制备方法 | |
CN101607061A (zh) | 一种保护胃粘膜的药物组合及其制备方法 | |
CN101301378B (zh) | 一种止咳润肺的药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: HUNAN JIUDIAN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHU ZHIHONG Effective date: 20121226 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20121226 Address after: 410005, Hunan, Changsha province Furong Road, No. 368 BOBO world city CTA wealth center, 24 floor Applicant after: Hunan Jiudian Pharmaceutical Co., Ltd. Address before: 410005, Hunan, Changsha province Furong South Road section 368 BOBO world city CTA wealth center, 24 floor Applicant before: Zhu Zhihong |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120523 |